Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed Feb 29, 2024 · 10-K · 60 days after period end · 0001636282-24-000005
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | $168.00K | $3.64M | — |
| Net Income | -$63.18M | -$18.82M | -$20.45M | -$22.71M |
| EPS Diluted | — | — |
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
| — |
| -$0.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 29, 2024 · 60 d after period end
